



5.21.142

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	May 8, 2020
<b>Subject:</b>	Koselugo	<b>Page:</b>	1 of 5

---

**Last Review Date:** June 16, 2022

---

## Koselugo

### Description

#### Koselugo (selumetinib)

#### Background

Koselugo (selumetinib) is an inhibitor of mitogen-activated protein kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Both MEK and ERK are critical components of the RAS-regulated RAF-MEK-ERK pathway, which is often activated in different types of cancers. Koselugo inhibits ERK phosphorylation and reduces neurofibroma numbers, volume, and proliferation (1).

#### Regulatory Status

FDA-approved indication: Koselugo is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) (1).

Koselugo carries warnings for cardiomyopathy, ocular toxicity, gastrointestinal toxicity, skin toxicity, increased creatinine phosphokinase (CPK), and increased vitamin E levels and risk of bleeding (1).

Cardiomyopathy, defined as a decrease in left ventricular ejection fraction (LVEF)  $\geq$  10% below baseline, has occurred in patients treated with Koselugo. Ejection fraction should be assessed prior to initiating treatment, every 3 months during the first year of treatment, every 6 months thereafter, and as clinically indicated (1).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	May 8, 2020
<b>Subject:</b>	Koselugo	<b>Page:</b>	2 of 5

---

Ocular toxicities have also been reported in patients treated with Koselugo. This includes: blurred vision, photophobia, cataracts, ocular hypertension, and serious toxicities such as retinal vein occlusion and retinal pigment epithelial detachment. Comprehensive ophthalmic assessments should be conducted prior to initiating Koselugo, at regular intervals during treatment, and for new or worsening visual changes (1).

Koselugo can cause fetal harm when administered to a pregnant woman. Pregnant women should be advised of the potential risk to a fetus. Females of reproductive potential should be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose. Males with female partners of reproductive potential should be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose (1).

The safety and effectiveness of Koselugo in pediatric patients less than 2 years of age have not been established (1).

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Koselugo may be considered **medically necessary** in patients 2 years of age or older with neurofibromatosis type 1 (NF1) and if the conditions indicated below are met.

Koselugo may be considered **investigational** in patients less than 2 years of age and for all other indications.

## Prior-Approval Requirements

**Age** 2 years of age or older

### Diagnosis

Patient must have the following:

Neurofibromatosis Type 1 (NF1)

**AND ALL** of the following:

a. Patient is symptomatic

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	May 8, 2020
<b>Subject:</b>	Koselugo	<b>Page:</b>	3 of 5

---

- b. Patient has plexiform neurofibromas (PN) that are inoperable
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose
- d. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose
- e. Baseline ophthalmic assessment has been done and prescriber agrees to monitor for ocular toxicities
- f. Baseline left ventricular ejection fraction (LVEF) has been assessed and prescriber agrees to monitor LVEF

## Prior – Approval *Renewal* Requirements

**Age** 2 years of age or older

### Diagnosis

Patient must have the following:

Neurofibromatosis Type 1 (NF1)

**AND ALL** of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose
- c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Koselugo and for 1 week after the last dose
- d. Prescriber agrees to monitor for ocular toxicities
- e. Prescriber agrees to monitor left ventricular ejection fraction (LVEF)

## Policy Guidelines

### Pre - PA Allowance

None

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	May 8, 2020
<b>Subject:</b>	Koselugo	<b>Page:</b>	4 of 5

---

## Prior - Approval Limits

**Quantity** 720 capsules per 90 days

**Duration** 12 months

## Prior – Approval *Renewal* Limits

Same as above

## Rationale

### Summary

Koselugo (selumetinib) is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1). Koselugo carries warnings for cardiomyopathy, ocular toxicity, gastrointestinal toxicity, skin toxicity, increased creatinine phosphokinase (CPK), and increased vitamin E levels and risk of bleeding. Koselugo can cause fetal harm when administered to a pregnant woman. The safety and effectiveness of Koselugo in pediatric patients less than 2 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use of Koselugo while maintaining optimal therapeutic outcomes.

### References

1. Koselugo [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2021.
2. NCCN Drugs & Biologics Compendium<sup>®</sup> Selumetinib 2022. National Comprehensive Cancer Network, Inc. Accessed on April 21, 2022.

## Policy History

Date	Action
May 2020	Addition to PA
June 2020	Annual review
September 2020	Annual review and reference update
June 2021	Annual editorial review
June 2022	Annual review and reference update

# 5.21.142

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2022
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	May 8, 2020
<b>Subject:</b>	Koselugo	<b>Page:</b>	5 of 5

---

## Keywords

**This policy was approved by the FEP® Pharmacy Medical Policy Committee on June 16, 2022 and is effective on July 1, 2022.**